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RESEARCH ARTICLE

CNS myelination and remyelination
depend on fatty acid synthesis by
oligodendrocytes
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Zürich, Zürich, Switzerland; 2Center for Medical Research, Medical University of
Graz, Graz, Austria; 3Division of Endocrinology, Metabolism and Lipid Research,
Washington University Medical School, St. Louis, United States

Abstract Oligodendrocytes (OLs) support neurons and signal transmission in the central nervous
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system (CNS) by enwrapping axons with myelin, a lipid-rich membrane structure. We addressed the
significance of fatty acid (FA) synthesis in OLs by depleting FA synthase (FASN) from OL progenitor
cells (OPCs) in transgenic mice. While we detected no effects in proliferation and differentiation
along the postnatal OL lineage, we found that FASN is essential for accurate myelination, including
myelin growth. Increasing dietary lipid intake could partially compensate for the FASN deficiency.
Furthermore, FASN contributes to correct myelin lipid composition and stability of myelinated
axons. Moreover, we depleted FASN specifically in adult OPCs to examine its relevance for
remyelination. Applying lysolecithin-induced focal demyelinating spinal cord lesions, we found that
FA synthesis is essential to sustain adult OPC-derived OLs and efficient remyelination. We conclude
that FA synthesis in OLs plays key roles in CNS myelination and remyelination.
DOI: https://doi.org/10.7554/eLife.44702.001
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Introduction
Under the control of a complex bidirectional signaling program (Herbert and Monk, 2017;
Klingseisen and Lyons, 2018; Nave and Werner, 2014; Osso and Chan, 2017), oligodendrocytes
(OLs) encase central nervous system (CNS) axons with myelin, a highly organized and compacted
multi-membrane structure. Myelination allows rapid transmission of action potentials and preserves
axonal integrity by multiple mechanisms, including metabolic support by OLs (Fünfschilling et al.,
2012; Lee et al., 2012; Simons et al., 2014). Thus, loss of myelin in diseases of diverse etiology,
such as in multiple sclerosis, ultimately results in axonal degeneration and clinical deterioration of
affected patients (Franklin and Ffrench-Constant, 2017; Nave and Werner, 2014; Saab and Nave,
2017). During postnatal development, OL progenitor cells (OPCs) undergo a tightly orchestrated
differentiation program leading to mature OLs that contact axons and wrap them with myelin
(Nave and Werner, 2014). A significant population of OPCs remains resident in the adult CNS, designated adult OPCs (aOPCs) (Dimou and Gallo, 2015; Franklin and Ffrench-Constant, 2017). Upon
a demyelinating injury, aOPCs are activated, migrate to the lesion site, proliferate, undergo differentiation, and mature into OLs that remyelinate axons. Hence, aOPCs-derived OLs substitute for preexisting ones which are lost upon demyelination (Crawford et al., 2016; Franklin and Ffrench-Constant, 2017). However, this program often fails in myelin-defective lesions leaving axons particularly
vulnerable. While a number of exogenous and endogenous factors are known to restrict the
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regenerative potential of aOPCs (Franklin and Ffrench-Constant, 2017; Miron, 2017), the roles of
modulators of their metabolic state remain largely unknown.
Myelin is characterized by an exceptionally high lipid content (~80% of dry weight) (Chrast et al.,
2011; Nave and Werner, 2014; Schmitt et al., 2015). Fatty acids (FAs) are fundamental building
blocks for both glycolipids and phospholipids, which comprise the largest proportion of myelin
membrane lipids (Harayama and Riezman, 2018). FAs can be acquired from the pool present in the
circulation due to dietary intake (essential and non-essential FAs), through horizontal flux from adjacent cells (essential and non-essential FAs), or are cell-endogenously synthesized (non-essential FAs)
(Camargo et al., 2017; Currie et al., 2013). However, the relative contribution of uptake versus synthesis to the final pool of FAs in OLs at different stages of differentiation remains to be determined.
The mTORC1-SCAP signaling axis regulates a plethora of lipogenic pathways via cleavage of Sterol Regulatory Element-Binding Proteins (SREBPs). These transcription factors are major modulators
of FA and cholesterol metabolism (Laplante and Sabatini, 2012; Porstmann et al., 2008), including
in OLs (Camargo et al., 2017). Accordingly, depletion of mTOR (Wahl et al., 2014), the functionally
required mTORC1 subunit Raptor (Bercury et al., 2014; Lebrun-Julien et al., 2014) or SCAP
(Camargo et al., 2017) in OLs causes reduced radial growth of myelin, mimicking the phenotype
triggered by depletion of the SREBP-downstream target squalene synthase, an enzyme required for
cholesterol synthesis (Saher et al., 2005). Genetic depletion of Raptor and SCAP in OLs results also
in reduced expression of FA synthase (FASN) (Camargo et al., 2017; Lebrun-Julien et al., 2014) –
the enzyme responsible for the synthesis of the 16-carbon palmitic acid that is used as substrate for
subsequent synthesis of longer FAs (Currie et al., 2013). However, the functional role of endogenous FA synthesis in OL differentiation and CNS myelination, and how diminished FASN expression
impacts upon the observed mTORC1/SCAP-knockout phenotypes, is not clear.
We previously found that de novo FA synthesis is essential for correct onset of myelination by
Schwann cells, the myelinating cells of the peripheral nervous system (PNS) (Montani et al., 2018).
In the present study, we have tested whether OLs rely also on endogenous FA synthesis for developmental myelination. Furthermore, we investigated whether remyelination after injury depends on FA
synthesis by OLs. In development, we addressed this question by genetically depleting FASN in the
OL lineage of transgenic mice. To analyze the role of endogenous FA synthesis in remyelination of
adults, we deleted FASN specifically from aOPCs and their progeny, in conjunction with a focal
demyelinating spinal cord lesion using the well-established lysolecithin gliotoxin-injection model
(Blakemore and Franklin, 2008). Our data reveal that endogenous FA synthesis in OLs is required
for correct CNS myelination in development and essential for efficient remyelination in adulthood.

Results
Depletion of FASN in oligodendrocytes
OLs have the capacity to cover numerous axons with multiple membrane layers to form myelin
(Nave and Werner, 2014). Thus, we hypothesized that OLs may depend on endogenous FASNdriven FA synthesis for myelin production. Indeed, OLs transcribe FASN at high levels (http://web.
stanford.edu/group/barres_lab/cgi-bin/igv_cgi_2.py?lname=Fasn) (Zhang et al., 2014). To test our
hypothesis, we used mouse genetics to ablate FASN specifically in the OL lineage. Conditionally
mutant Fasnlox/lox mice (Chakravarthy et al., 2005) were crossed with mice expressing Cre recombinase under the control of Olig2 gene regulatory elements (Schüller et al., 2008) (Figure 1a). The
resulting Fasn mutants were viable, fertile and born according to Mendelian distribution. Loss of
FASN expression was confirmed by immunohistochemistry in differentiated (CC1+) OLs of postnatal
day (P) 14 mutants in spinal cord white matter (Figure 1b,c), in agreement with highly efficient
recombination in OL lineage cells as monitored by inclusion of the Cre-dependent reporter Rosa26loxPstoploxP-YFP allele (Srinivas et al., 2001) (Figure 1—figure supplement 1a,b). Comparable
loss of FASN was also found in the gray matter (Figure 1—figure supplement 2a,b). Note that large
motoneurons in the ventral horn showed strong FASN expression, which was retained in mutant
mice (Figure 1—figure supplement 2a,b).
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Figure 1. Generation of mutant mice lacking FASN in the oligodendrocyte lineage. (a) Experimental strategy of
conditional Fasn allele inactivation upon Olig2-driven Cre expression in vivo. (b) Schematic of thoracic spinal cord.
Square insert ‘c’: White matter (WM) where subsequent immunostaining images were acquired. GM = gray matter
(c) Representative immunostaining of cross-sectioned spinal cord from P14 CT and cMU mice, n = 3 mice
examined for each, CT and cMU. Prominent cytoplasmic FASN expression in differentiated OLs (CC1+; examples
indicated by arrowheads) in CT, but not in cMU. Nuclear marker: DAPI. Scale bars: 20 mm. CT = control,
cMU = conditional mutant, GM = gray matter, WM = white matter.
DOI: https://doi.org/10.7554/eLife.44702.002
The following figure supplements are available for figure 1:
Figure supplement 1. Recombination efficiency in spinal cord white matter.
DOI: https://doi.org/10.7554/eLife.44702.003
Figure supplement 2. FASN expression in gray matter oligodendrocytes of CT but not in cMU mice.
DOI: https://doi.org/10.7554/eLife.44702.004

FASN is dispensable for proliferation and differentiation along the
oligodendrocyte lineage
Before OLs reach the myelinating stage, their progenitors (OPCs) need to proliferate, differentiate
and mature. In some proliferating cells such as in cancer and neuronal progenitors, FASN activity is
required to support increased metabolic demands (Currie et al., 2013; Knobloch et al., 2013).
Thus, we analyzed OL proliferation by EdU incorporation but found no detectable differences
between mutants and controls at both P4 and P10 (Figure 2a,b). Next, we addressed whether lack
of FASN may affect differentiation along the OL lineage during development. Initial immunohistochemical analyses revealed marginal (if any) FASN expression in white matter OPCs (PDGFRa+ cells)
of the P14 spinal cord (Figure 2—figure supplement 1a), compared to high levels in differentiated
OLs (CC1+ cells) (Figure 2—figure supplement 1a). Further comparative analyses of mutant and
control mice yielded no significant differences in the percentages of OPCs (PDGFRa+ Olig2+) (Figure 2—figure supplement 1b,c), total OL lineage cells (Olig2+) (Figure 2c,d and e) and differentiated OLs (CC1+ Olig2+) (Figure 2c,d and e) in spinal cord white matter at P4, P10 and P14. Taken
together, these data indicate that FASN is not required for correct proliferation and differentiation
of the OL lineage to CC1+ cells during postnatal development.
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Figure 2. De novo fatty acid synthesis is not required to achieve correct numbers of oligodendrocyte lineage cells during development. (a)
Representative immunostaining of ventral white matter in cross-sectioned spinal cords of P4 and P10 mice identifying proliferating (EdU+) OLs (Olig2+;
examples indicated by arrowheads), n = 3 mice for each, CT and cMU. Nuclear marker: DAPI. Scale bar: 50 mm, applying to entire panel. (b)
Corresponding graphs to (a) with quantification of percentage of proliferating OLs (EdU+ Olig2+) over total number of OLs (Olig2+) in spinal cord
Figure 2 continued on next page
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Figure 2 continued
white matter of CT and cMU mice at P4 and P10. Data points represent n = 3 mice for each, CT and cMU; random fields of both dorsal and ventral
white matter of 4 sections quantified per animal, with at least 83 Olig2+ cells quantified per section (unpaired two-tailed two sample Student’s t-test; at
P4: cMU vs. CT, p=0.6876, t = 0.4326; P10: cMU vs. CT, p=0.5448, t = 0.6608). (c) Representative immunostaining of ventral white matter in crosssectioned spinal cords from P4, P10, and P14 mice identifying differentiated OLs (CC1+; examples indicated by arrowheads), OLs (Olig2+) and total
number of cells (DAPI+), n = 3 mice for each, CT and cMU at P4 and P10, n = 5 mice for each, CT and cMU at P14. Nuclear marker: DAPI. Scale bar: 50
mm, applying to entire panel. (d, e) Corresponding graphs to (c) with quantification of percentage of total OLs (Olig2+) (d) and differentiated OLs (CC1
+ Olig2+) (e) over total number of cells (DAPI+), in the spinal cord white matter of CT and cMU mice at P4, P10 and P14. Data points represent n = 3
mice for each, CT and cMU at P4 and P10, and n = 5 mice for each, CT and cMU at P14. Random fields of both dorsal and ventral white matter of at
least 3 sections quantified per animal, with at least 83 Olig2+ cells quantified per section (unpaired two-tailed two sample Student’s t-test; % Olig2+/
DAPI+ at P4: cMU vs. CT, p=0.8280, t = 0.2319; at P10: cMU vs. CT, p=0.6694, t = 0.46; at P14: cMU vs. CT, p=0.3340, t = 1.028; % CC1+ Olig2+ / DAPI
+ at P4: cMU vs. CT, p=0.3405, t = 1.081; at P10: cMU vs. CT, p=0.8490, t = 0.2031; at P14: cMU vs. CT, p=0.2061, t = 1.376). Bars represent
mean ±SEM. CT = control, cMU = conditional mutant.
DOI: https://doi.org/10.7554/eLife.44702.005
The following figure supplement is available for figure 2:
Figure supplement 1. FASN expression in oligodendrocyte progenitors is marginal and dispensable for their early maintenance.
DOI: https://doi.org/10.7554/eLife.44702.006

De novo fatty acid synthesis is critical for accurate CNS myelination,
including radial myelin growth
Based on the observed high levels of FASN expression in differentiated (CC1+) OLs, we addressed
next whether these cells rely on endogenous FA synthesis to myelinate. Thus, we performed EM
ultrastructural morphological analysis of the ventral spinal cord white matter from control and
mutant mice at P14 (Figure 3). We found that mutant mice exhibited more axons not encased by
myelin compared to controls (69.57 ± 3.75% in mutants vs. 53.56 ± 2.37% in controls) (Figure 3a,b).
Moreover, g-ratio analysis (i.e. ratio of axon to fiber (axon + myelin) diameter) revealed that mutant
myelinated axons had overall thinner myelin compared to controls (Figure 3c). These data were confirmed by analysis of the correlation of g-ratio and fiber diameter with axon diameter (Figure 3d,e).
To understand whether lack of FASN resulted in persistently reduced myelination of axons, we compared the ultrastructural morphology of white matter of the ventral spinal cord of mutant versus control mice at P180. Although myelination progressed in both cases, a higher percentage of not-yet
myelinated axons persisted in the spinal cord white matter of mutant mice (15.21 ± 2.92% in mutants
vs. 6.59 ± 1.01% in controls) (Figure 3g). In addition, marked hypomyelination of mutant axons also
persisted (Figure 3f, arrows), confirmed by g-ratio analysis (Figure 3h,i and j). We conclude that
endogenous FA synthesis in OLs is critical for accurate myelination in the spinal cord, including efficient myelin growth. Our findings may reflect that lack of endogenous FA synthesis limits total myelin production of each mutant OL and/or the number of myelin sheaths that can be generated.
Other contributing factors to the mutant OL phenotype might include altered timing in the onset of
individual myelin sheath formation.
To examine whether anatomically differently located OLs are similarly dependent on endogenous
FA synthesis, we extended our study to the optic nerve. As observed in the spinal cord, high recombination efficiency in OL lineage cells was also found in this structure (Figure 3—figure supplement
1a,b). In line with our findings in the spinal cord, P14 optic nerves of mutant mice displayed a higher
percentage of axons not-yet encased by myelin compared to controls (84.08 ± 0.33% in mutants vs.
75.68 ± 0.77% in controls) (Figure 3—figure supplement 2a,b). Although the onset of myelination
progressed in both mutants and controls, also P180 mutant optic nerves retained more axons not
encased by myelin (21.16 ± 5.1% in mutants vs. 4.29 ± 1.6% in controls) (Figure 3—figure supplement 2f, false colored, and g). Overall, no significant hypomyelination was detectable in optic
nerves of mutant mice in early development (P14) (Figure 3—figure supplement 2c,d and e). Analysis of P180 optic nerves revealed, however, that mutant OLs failed to support ongoing myelin
growth accurately, resulting in pronounced hypomyelination in adulthood (Figure 3—figure supplement 2f). This observation was confirmed by overall g-ratio quantification (Figure 3—figure supplement 2h) and correlation analyses of g-ratio and fiber diameter versus axon diameter (Figure 3—
figure supplement 2i,j). We conclude that FASN activity in OLs is required for accurate myelination
also in the optic nerve, albeit with subtle differences to the spinal cord.
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Figure 3. De novo fatty acid synthesis by oligodendrocytes is essential to achieve accurate myelination in the spinal cord. (a) Representative EM images
of P14 control (CT, a’ and a’’) and conditional mutant (cMU, b’ and b’’) white matter from the ventral funiculi of lumbar spinal cords. cMUs show more
naked axons, not-yet enwrapped by myelin, when compared to CTs. cMUs also display thinner myelin (examples indicated by arrows). Scale bars: 2 mm.
(b) Corresponding graph with quantification of percentage of not myelinated axons at P14. Data points represent n = 3 mice for each, CT and cMU,
with at least 590 axons quantified per animal in random fields selected in the same anatomical area (unpaired two-tailed two sample Student’s t-test; at
P14: cMU vs. CT, p=0.0225, t = 3.614), *p<0.05. (c) Overall hypomyelination at P14 in cMU as shown by g-ratio analysis. Data points represent n = 3
mice for each, CT and cMU (unpaired two-tailed two sample Student’s t-test; at P14: cMU vs. CT, p=0.0025, t = 6.731), **p<0.01. (d, e) Linear
correlation of g-ratio versus axon diameter (d) and of fiber diameter versus axon diameter (e), in the ventral white matter spinal cord of cMU compared
to CT at P14. 100 myelinated axons per mouse analyzed in random fields selected in the same anatomical area, n = 3 mice for each, CT and cMU. (f)
Representative EM images of P180 CT and cMU white matter from ventral funiculi of lumbar spinal cords. cMUs show more naked axons (false colored
in orange) compared to CTs. cMU axons are encased by thinner myelin (examples indicated by arrows) compared to CTs. Scale bars: 5 mm. (g)
Corresponding graph with quantification of percentage of not myelinated axons at P180. Data points represent n = 3 mice for each, CT and cMU, with
at least 220 axons quantified per animal, in random fields selected in the same anatomical area (unpaired two-tailed two sample Student’s t-test; at
P180: cMU vs. CT, p=0.0493, t = 2.791), *p<0.05. (h) Overall hypomyelination at P180 in cMU compared to CT, as shown by g-ratio analysis. Data points
represent n = 3 mice for each, CT and cMU (unpaired two-tailed two sample Student’s t-test; at P180: cMU vs. CT, p=0.0027, t = 6.651), **p<0.01. (i, j)
Linear correlation of g-ratio versus axon diameter (i) and of fiber diameter versus axon diameter (j), in the ventral white matter spinal cord of cMU
compared to CT at P180. At least 65 myelinated axons per mouse analyzed in random fields selected in the same anatomical area, n = 3 mice for each,
CT and cMU. Bars represent mean ±SEM. CT = control, cMU = conditional mutant.
DOI: https://doi.org/10.7554/eLife.44702.007
The following figure supplements are available for figure 3:
Figure supplement 1. Recombination efficiency in the optic nerve.
Figure 3 continued on next page
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Figure 3 continued
DOI: https://doi.org/10.7554/eLife.44702.008
Figure supplement 2. De novo fatty acid synthesis by oligodendrocytes is essential to achieve accurate myelination of the optic nerve.
DOI: https://doi.org/10.7554/eLife.44702.009
Figure supplement 3. De novo fatty acid synthesis by oligodendrocytes is essential to achieve accurate myelination of the corpus callosum.
DOI: https://doi.org/10.7554/eLife.44702.010

Since the corpus callosum is often explored in myelin research, we examined also this brain
region in the adult. Similar to our findings in the spinal cord and in the optic nerve, an increased fraction of axons that were not enwrapped by myelin was detected in the corpus callosum of P180
mutant mice (72.27 ± 0.98% in mutants vs. 63.53 ± 2.41% in controls) (Figure 3—figure supplement
3a,b). In addition, myelinated axons displayed relatively thinner myelin in mutants, as indicated by
the higher g-ratio values compared to controls (Figure 3—figure supplement 3a,c) and confirmed
by scatter plots of g-ratio and fiber diameter versus axonal diameter (Figure 3—figure supplement
3d,e).
Taken together, our studies of different CNS regions revealed that endogenous FA synthesis by
OLs is required for correct myelination in various areas. More detailed comparisons require further
investigations, including complementary approaches to alleviate technical limitations. Such examinations may well uncover more subtle variations between these regions, possibly relating to the physiological context of each environment, including local differences in astrocyte coupling, or potential
intrinsic differences between oligodendrocyte lineage cells (Dimou and Simons, 2017;
Marques et al., 2016).

De novo fatty acid synthesis contributes to the stability of myelinated
axons and correct CNS myelin lipid composition
A further characteristic feature in spinal cord tissue of P14 mutant mice were some aberrant vacuolated myelin-axon profiles (Figure 4a), confirmed by quantification (3.81 ± 0.15% in mutants vs. 0.25
± 0.08% in controls) (Figure 4b). These structures resembled those observed in the PNS when
Schwann cells lack FASN (Montani et al., 2018). Irregular myelin (Figure 4a, arrowheads) was often
surrounding axons which appeared compressed (Figure 4a, asterisks). Similarly, examination of optic
nerves revealed a comparable increase in anomalous myelin-axon profiles in mutant mice (5.41 ±
1.0% in mutants vs. 0.75 ± 0.19% in controls) (Figure 4—figure supplement 1a,b).
Since FAs are key structural components of cellular membranes, we investigated the lipid composition of myelin in mutant mice that lack FA synthesis in OLs compared to controls. To this end, we
quantified FAs and FA-derived lipid classes in myelin purified from spinal cords of P60 mice. No significant alterations were detectable in essential (diet-derived), conditional-essential (derived from
essential) and non-essential FAs (Figure 4c, Figure 4—figure supplement 2a) of mutants. Furthermore, we found no difference in the content of palmitate, the direct product of FASN enzymatic
activity in mutant vs. control myelin (Figure 4d). Myelin from spinal cords of mutant mice contained
also similar amounts of ceramides (Figure 4e, Figure 4—figure supplement 2b), cerebrosides
(Figure 4f, Figure 4—figure supplement 2c), and sphingomyelin (Figure 4g, Figure 4—figure supplement 2d) compared to controls. Besides some minor alterations (Figure 4—figure supplement
2), strikingly elevated total levels of phosphatidylserines were found in mutants compared to controls (393.5 ± 25.53 in mutants vs. 269.6 ± 4.38 in controls, pmol/mg of proteins) (Figure 4i, Figure 4—figure supplement 2g). We conclude that lack of endogenous FA synthesis in OLs has a
modest influence on the resulting lipid composition of myelin.

Transcriptome analysis of optic nerves of Fasn mutant mice reveals
oligodendrocyte defects in late stages of maturation, including
myelination
Our results obtained so far indicated that FASN is critical for timely onset of OLs myelination and
subsequent radial growth of CNS myelin, but does not play a major role in OL lineage progression
based on expression of Olig2, PDGFRa, and CC1 as analytic markers. It is well known, however, that
aside from being building blocks for different lipid species, FAs play other key roles such as a source
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Figure 4. De novo fatty acid synthesis by oligodendrocytes is required to maintain structural stability of
myelinated axons. (a) Exemplary EM images of aberrant myelin-axon profiles showing vacuolation (examples
indicated by arrowheads) in the ventral white matter of spinal cords of P14 cMUs. Where identifiable, axons
associated with aberrant structures are indicated by asterisks. Scale bars: I = 5 mm, II = 2 mm, III = 2 mm, IV = 2 mm,
V = 5 mm, VI = 2 mm, VII = 2 mm. (b) Corresponding graph with quantification of the percentage of aberrant
myelin-axon profiles. Data points represent n = 3 mice for each, CT and cMU (unpaired two-tailed two sample
Student’s t-test; at P14: cMU vs. CT p<0.0001, t = 21.16), ***p<0.001. At least 8300 axons per mouse analyzed in
random fields selected in the same anatomical area. (c) Total FA composition of myelin purified from spinal cords
of P60 CT and cMU mice, divided in non-essential FAs (NEss), conditional-essential FAs (Cond Ess) and essential
FAs (Ess). Data points represent n = 3 mice for CT and n = 4 mice for cMU (unpaired two-tailed two sample
Student’s t-test; NEss: cMU vs. CT, p=0.2609, t = 1.267; Cond Ess: cMU vs. CT, p=0.6625, t = 0.4635; Ess: cMU vs.
CT, p=0.4435, t = 0.8317). (d) Quantification of the most abundant FAs found in myelin purified from spinal cords
of CT and cMU mice. Data points represent n = 3 mice for CT and n = 4 mice for cMU (unpaired two-tailed two
sample Student’s t-test; Oleic: cMU vs. CT, p=0.2525, t = 1.293; Palmitic: cMU vs. CT, p=0.7377, t = 0.3542; Stearic:
cMU vs. CT, p=0.4966, t = 0.7328). (e, f, g) Content of ceramides (e), cerebrosides (f) and sphingomyelin (g) in
myelin isolated from spinal cords of cMU compared to CT mice. Data points represent n = 4 mice for each, CT
and cMU (unpaired two-tailed two sample Student’s t-test; ceramides: cMU vs. CT, p=0.2822, t = 1.181;
Figure 4 continued on next page
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Figure 4 continued
cerebrosides: cMU vs. CT, p=0.2722, t = 1.209; sphingomyelin: cMU vs. CT, p=0.2310, t = 1.333). (h, i, j, k) Total
content of phosphatidylinositols (PI), phosphatidylserines (PS), phosphatidylcholines (PC) and
phosphatidylethanolamines (PE) in myelin isolated from spinal cords of CT and cMU mice. Data points represent
n = 4 mice for each, CT and cMU (unpaired two-tailed two sample Student’s t-test; PI: cMU vs. CT, p=0.1765,
t = 1.532; PS: cMU vs. CT, p=0.0031, t = 4.784; PC: cMU vs. CT, p=0.2698, t = 1.216; PE: cMU vs. CT, p=0.7236,
t = 0.3706), **p<0.01. Bars represent mean ±SEM. CT = control, cMU = conditional mutant.
DOI: https://doi.org/10.7554/eLife.44702.011
The following figure supplements are available for figure 4:
Figure supplement 1. De novo fatty acid synthesis by oligodendrocytes supports structural stability of myelinated
axons in the optic nerve.
DOI: https://doi.org/10.7554/eLife.44702.012
Figure supplement 2. Lipid profiles of spinal cord myelin of adult control and FASN mutant mice.
DOI: https://doi.org/10.7554/eLife.44702.013

of energy by oxidation (Lodhi and Semenkovich, 2014), through palmitoylation of proteins
(Resh, 2016; Salaun et al., 2010), and by modulating transcriptional networks (Ahmadian et al.,
2013). In this context, we have previously identified activation of PPARg as a mediator of FASN in
triggering onset of PNS myelination (Montani et al., 2018). In view of these findings, molecular
alterations due to lack of FASN in the OL lineage appeared likely. Given that we had not observed
significant alterations in OL differentiation up to the CC1+ stage, such potential changes are predicted to reflect functions of OL-derived FASN in the transition of CC1+ OLs to the final stages of
maturation up to myelination completion. We addressed this issue by comparing the optic nerve
transcriptome of P14 mutant and control mice (Figure 5—source data 1). In line with our morphological findings, Metacore enrichment analysis revealed repression of GeneOntology Processes associated with development of the nervous system, OL differentiation, and myelination (Figure 5a,b). A
more detailed Metacore Pathway analysis highlighted downregulation of known regulatory axes of
OL maturation and myelination, including cytoskeleton proteins, cell-cell and ECM-cell interactions,
as well as epigenetic and transcriptional regulation (Figure 5a,b). To explore these dysregulations
further, we compared them to OLs single cell transcriptomic data (Marques et al., 2016). This comparison revealed that mutant optic nerves displayed increased expression of a subset of transcripts
enriched in mature OLs (MOL 1–6 in ref. Marques et al., 2016) such as Klk6, Sepp1, and Glul. In parallel, reduced expression of several transcripts enriched in myelin-forming OLs (MFOL1/2 in ref.
Marques et al., 2016) including Ctps, Sirt2, Gpr17, Olig1, Mag and Mobp was identified. Following
up on these findings by a candidate approach, we detected also reduced expression of transcripts
encoding well known myelin-associated proteins such as PLP1, MBP and CNP, and of major regulators of OLs including Sox10, Sox8, and Myrf (Bujalka et al., 2013; Hornig et al., 2013; Li and
Richardson, 2016; Turnescu et al., 2018) (Figure 5c, Figure 5—figure supplement 1). Combined
with our previous findings, the dysregulated molecular fingerprint revealed by these data is consistent with a functional role for FASN in late OL maturation and myelination. However, the impaired
myelination in mutant mice may also contribute to the transcriptome differences compared to
controls.

Increased dietary intake of lipids can partially rescue lack of fatty acid
synthesis by oligodendrocytes
Increasing dietary intake of lipids was unable to rescue lack of endogenous FA synthesis by Schwann
cells in PNS myelination, instead being surprisingly detrimental (Montani et al., 2018). To investigate whether such a treatment could rescue myelination if OLs are deficient in FA synthesis, we fed
mutant and control mice either a 60% high fat diet (HFD; % of caloric intake from fat, enriched in
palmitic acid; complete FA content in Materials and methods), previously shown to be capable of
rescuing diminished lipogenesis in astrocytes in vivo (Camargo et al., 2012; Camargo et al., 2017),
or a standard diet (STD; complete FA content in Materials and methods). Pregnant females and subsequently born pups were fed with the different diets from E14 up to P40, the time of analysis
(Figure 6a). We found that the HFD regimen lead to improved myelin radial growth in the spinal
cord of mutant mice compared to mutant mice fed with STD (Figure 6b,c and d). There were no
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Figure 5. Transcriptome analysis of optic nerves of Fasn mutant mice reveal oligodendrocyte defects in late stages of maturation, including
myelination. (a, b) GeneOntology analysis depicting biological processes affected by down-regulated (a) and up-regulated (b) transcripts in P14 optic
nerves of mutant (cMU) mice. Metacore Pathway analysis showing pathways affected by downregulated (a) and upregulated (b) transcripts in P14 optic
nerves of cMU mice. Data points represent the count of regulated transcript for each category and pathway. (c) Heat map of RNA-seq data of CT and
Figure 5 continued on next page
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Figure 5 continued
cMU optic nerves at P14, depicting Fasn and selected down- and up-regulated modulators of OL differentiation, maturation and myelination
(FDR < 0.05). Markers identified by comparison with OLs single cell sequencing data (Marques et al., 2016) are marked with an asterisk. n = 3 mice for
cMU, n = 4 mice for CT. CT = control, cMU = conditional mutant, MFOLs = myelin-forming oligodendrocytes, MOLs = mature oligodendrocytes
(Marques et al., 2016).
DOI: https://doi.org/10.7554/eLife.44702.014
The following source data and figure supplement are available for figure 5:
Source data 1. Expressed transcripts in optic nerves from control and cMU mice at P14.
DOI: https://doi.org/10.7554/eLife.44702.016
Figure supplement 1. FASN deficiency is correlated with molecular signs of defective oligodendrocyte maturation.
DOI: https://doi.org/10.7554/eLife.44702.015

significant effects of HFD on radial myelin growth in control mice (Figure 6b,c and d). Myelinated
fibers in the spinal cord of mutant mice treated with HFD were still hypomyelinated compared to
those of control mice under HFD or STD, but less so than those of mutant mice under STD
(Figure 6b,c and d). We conclude that lack of endogenous FA synthesis in OLs during development
can be partially compensated by increasing dietary lipid intake.

Depletion of fatty acid synthase in adult oligodendrocyte progenitors
to study CNS remyelination
Following demyelination, new myelin is formed by aOPCs (Crawford et al., 2016; Franklin and
Ffrench-Constant, 2017). To address the significance of FA synthesis in this process, we conditionally ablated the Fasn gene specifically in aOPCs of transgenic mice using tamoxifen-activatable Cre
recombinase under the control of Pdgfra gene regulatory elements (Rivers et al., 2008). Recombination also activated YFP expression via the Cre-dependent reporter Rosa26-loxPstoploxP-YFP allele
(Srinivas et al., 2001) that was included in both, induced mutants (i-cMU) and induced control (CT)
mice. This experimental design allowed us to follow the fate of recombined cells (Figure 7a; Figure 7—figure supplement 1a,b). We then addressed how loss of FASN in aOPCs affects remyelination of a demyelinated focal lesion in the spinal cord, induced by injection of the gliotoxin
lysolecithin (experimental setting schematized in Figure 7b). Such lesions undergo a stereotyped
timed program of remyelination that is characterized by high proliferation of recruited aOPCs, followed by their differentiation into CC1+ OLs, OL maturation, and onset of remyelination within the
first 10–14 days post lesion (dpl), which is largely completed by 21 dpl (Fancy et al., 2011;
Zawadzka et al., 2010) (Figure 7b). Immunohistochemistry revealed high FASN expression in differentiated CC1+ aOPC-derived OLs in control mice at the lesion site 7 dpl (Figure 7c,d). As expected,
this expression was lost in mutant mice (Figure 7c,d).

Fatty acid synthesis is required to sustain aOPC-derived
oligodendrocytes during remyelination
To explore the role of FA synthesis in OLs during remyelination, we next analyzed FASN expression
in aOPCs and the effects of its depletion on their differentiation following demyelination. Comparable to our developmental studies, we found only marginal expression (if any) of FASN in aOPCs
located in acute lesions at 7 dpl (Figure 8—figure supplement 1a). Statistical analysis of immunohistochemical data revealed no significant difference between induced mutant and control mice in
numbers of recombined aOPCs (YFP+ PDGFRa+ Olig2+) when data were analyzed over time at 7,
10, 14 and 21 dpl (Figure 8—figure supplement 1b,c). However, if mutants and controls were statistically compared at the individual time points, a modest but significant reduction in recombined
aOPCs was apparent at 14 dpI and 21 dpl (unpaired two-tailed two sample Student’s t-test; i-cMU
vs. CT, at 14 dpl: p=0.0164, t = 3.027; at 21 dpl: p=0.041, t = 2.434). We conclude that FASN is
mostly dispensable for building up and maintaining the pool of aOPCs at the lesion site, given that
in our lesion model this pool is largely established at 10 dpI (Figure 8—figure supplement 1b,c). In
line with this interpretation, and similar to the developmental situation, we also found that FASN is
not essential for early proliferation of OL lineage cells (Olig2+) as tested by Ki67 immunohistochemistry at 7 dpl (Figure 8—figure supplement 2a,b).
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Figure 6. Increasing dietary lipid intake can partially compensate defects in radial myelin growth caused by lack of
endogenous fatty acid synthesis in oligodendrocytes. (a) Scheme of the experimental design. (b) Exemplary EM
micrographs of the ventral funiculus of the lumbar spinal cord from mutant (cMU) and control (CT) mice that were
fed a standard (STD) or a high-fat (HFD) diet. Scale bars: 5 mm. (c) Linear correlation of g-ratio versus axon
diameter. At least 84 myelinated axons analyzed per mouse, in random fields selected in the same anatomical
area, from n = 3 mice for each, CT and cMU, STD and HFD. (d) Overall hypomyelination in cMU compared to CT
fed STD at P40, and partial recovery of radial myelination in cMU fed with HFD, as shown by g-ratio analysis. Data
points represent n = 3 mice for each, CT and cMU, STD and HFD (one-way Anova; Treatment: p<0.0001, F3,8 =
113.2; with Sidak’s multiple comparisons test; cMU STD vs. CT STD: p<0.0001, t = 15.96; cMU HFD vs. CT HFD:
p=0.0002, t = 8.597; CT HFD vs CT STD: p=0.7703, t = 1.339; MU HFD vs. MU STD: p=0.0019, t = 6.025),
***p<0.001, **p<0.01. Bars represent mean ±SEM. STD = standard diet, HFD = high fat diet, CT = control,
cMU = conditional mutant.
DOI: https://doi.org/10.7554/eLife.44702.017
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Figure 7. Generation of tamoxifen-inducible PdgfraCreERT2:FASN-floxed conditionally mutant mice. (a) Tamoxifen-mediated nuclear translocation of
Pdgfra-driven CreERT2 induces conditional Fasn allele inactivation (i-cMU) and expression of yellow fluorescent protein (YFP). (b) Timeline of de-/remyelination experiments: Focal demyelination of the ventral spinal cord white matter was induced by injection of lysolecithin 4 weeks post-tamoxifen
administration. The tissue was analysed 7, 10, 14, 21 and 56 days post-lysolecithin injection (dpl). (c) Schematic of lysolecithin-induced demyelinated
focal lesion in the ventral funiculus of the thoracic spinal cord (level T12). Square insert indicates the area where immunostaining images were acquired.
(d) Representative immunostainings of lesioned areas in cross-sectioned thoracic spinal cords from CT and i-cMU mice 7 dpl, n = 3 mice analyzed for
each, CT and i-cMU. Note the prominent FASN expression in the cytoplasm of recombined aOPC-derived differentiated OLs (CC1+ YFP+ FASN+,
examples indicated by arrowheads) in CT, but not in i-cMU (CC1+ YFP+ FASN-, examples indicated by dotted lines) lesions. Nuclear marker: DAPI.
Scale bar: 20 mm, applies to entire panel. CT = control, i-cMU = inducible conditional mutant, dpl = days post-lysolecithin injection.
DOI: https://doi.org/10.7554/eLife.44702.018
The following figure supplement is available for figure 7:
Figure supplement 1. Recombination efficiency in spinal cords of PdgfraCreERT2:Rosa26-loxPstoploxP-YFP control animals induced with tamoxifen.
DOI: https://doi.org/10.7554/eLife.44702.019

Next, we examined whether FASN is required during differentiation and maturation of aOPCs
into myelinating OLs following demyelination. We found no difference in the number of recombined
total (Olig2+ YFP+) and differentiated (CC1+ Olig2+ YFP+) aOPC-derived OLs in mutant and control mice during early differentiation (7 dpI and 10 dpl) (Figure 8a,b and c). However, the number of
both recombined total (Olig2+ YFP+) and differentiated (CC1+ Olig2+ YFP+) OLs was substantially
lower in mutants compared to controls when remyelination was ongoing (14 dpl), with no major
recovery at 21 dpl (Olig2+ YFP+ cells per area (mm2) at 14 dpl: 98.4 ± 13.71 in mutants vs.
294.60 ± 28.05 in controls; at 21 dpl: 108.10 ± 11.93 in mutants vs. 237.70 ± 22.55 in controls;
CC1+ Olig2+ YFP+ cells per area (mm2) at 14 dpl: 45.18 ± 6.71 in mutants vs. 193.20 ± 11.73 in controls; at 21 dpl: 74.60 ± 5.00 in mutants vs. 183.00 ± 18.47 in controls) (Figure 8a,b and c). This
impairment was present already at the onset of remyelination (12 dpl; Figure 8—figure supplement
3a,b and c), suggesting that OL death might be involved. Cleaved caspase 3 (cC3) immunostaining
at 11 dpl did not detect a significant increase in the percentage of apoptotic differentiated recombined OLs (cC3+ CC1+ YFP+) in lesions of mutants compared to controls (Figure 8—figure supplement 3d,e). However, we found such cells at very low frequency, contributing to a rather high
variability between animals and limiting the power of our analysis and its interpretation. Thus, we
assume that our inability to find an expected significant increase in cC3-associated OL cell death in
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Figure 8. De novo fatty acid synthesis is required for maintaining the adult oligodendrocyte progenitor-derived oligodendrocyte population during
remyelination. (a) Representative immunostaining of lesions of control (CT) and inducible conditional mutant (i-cMU) mice on cross sections of ventral
white matter of the spinal cord at 7, 10, 14 and 21 days post-lysolecithin injection (dpl), n = 5 mice for each, CT and i-cMU. Images depict recombined
aOPC-derived differentiated OLs (CC1+ Olig2+ YFP+, examples indicated by arrowheads). Scale bar: 20 mm, applies to entire panel. (b, c)
Figure 8 continued on next page
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Figure 8 continued
Corresponding graphs with quantification of (b) recombined OLs (Olig2+ YFP+) and (c) recombined aOPC-derived differentiated OLs (CC1+ Olig2
+ YFP+) in lesion areas of ventral spinal cord white matter of CT and i-cMU mice at 7, 10, 14 and 21 dpl. Data were normalized per area. Data points
represent n = 5 mice for each, CT and i-cMU. Lesion areas of at least 4 sections quantified per animal (2-way Anova; (b) Genotype: p<0.0001, F1,32=
30.28; (c) Genotype: p<0.0001, F1,32= 84.52; with Tukey’s multiple comparisons test; (b) 7 dpl: i-cMU vs. CT, p=0.9829; 10 dpl: i-cMU vs. CT, p=0.6132;
14 dpl: i-cMU vs. CT, p<0.0001; 21 dpl: i-cMU vs. CT, p=0.0071; (c) 7 dpl: i-cMU vs. CT, p=0.9971; 10 dpl: i-cMU vs. CT, p=0.0900; 14: i-cMU vs. CT,
p<0.0001; 21 dpl: i-cMU vs. CT, p<0.0001), ***p<0.001, **p<0.01. Bars represent mean ± SEM. CT = control, i-cMU = inducible conditional mutant,
dpl = days post-lysolecithin injection.
DOI: https://doi.org/10.7554/eLife.44702.020
The following figure supplements are available for figure 8:
Figure supplement 1. FASN expression in adult oligodendrocyte progenitors is marginal and largely dispensable for their response following
demyelination.
DOI: https://doi.org/10.7554/eLife.44702.021
Figure supplement 2. FASN expression is dispensable for the proliferation of oligodendrocytes lineage cells in remyelination.
DOI: https://doi.org/10.7554/eLife.44702.022
Figure supplement 3. FASN is critical to sustain adult oligodendrocyte progenitor-derived oligodendrocytes during remyelination.
DOI: https://doi.org/10.7554/eLife.44702.023

mutants is likely due to either very fast removal of dying cells or cell death not marked by cC3-positivity, possibilities that we were unable to explore further due to technical limitations.
Overall our data indicate a crucial role for FA synthesis in sustaining aOPC-derived OLs during
remyelination. However, we cannot rule out that also the mild reduction in the number of aOPCs in
mutants at 14 dpI and 21 dpl makes some contribution to the observed phenotype. In this context,
we favor the interpretation that the observed decrease in CC1+ recombined OLs in mutant animals
during remyelination may promote a mild reaction of aOPCs, potentially with the goal of some compensation. If the recombined cells cannot be sustained and die while differentiating from aOPCs
towards myelinating oligodendrocytes, this may cause a slight reduction of the remaining numbers
of recombined aOPCs. Alternatively, aOPCs may have intrinsic differences in their dependency on
FASN compared to developmental OPCs with regard to survival. We consider this less likely given
the low expression of FASN by developmental OPCs and aOPCs.

Fatty acid synthesis is essential for efficient CNS remyelination
Based on our findings, we next investigated whether the observed drop in differentiated OLs causes
a failure of accurate remyelination in mutants. Thus, we analyzed the ultrastructural morphology of
remyelinating spinal cord lesions by comparative EM as remyelinated axons can be distinguished by
their relatively thin myelin compared to developmentally achieved myelination (Franklin and
Ffrench-Constant, 2017). Consistent with the reduced number of differentiated CC1+ OLs present
during the active remyelination phase at 14 dpl, we found that mutant mice displayed more axons
not encased by myelin (Figure 9a, false colored) compared to control mice (Figure 9a). Quantification confirmed these observations (35.63 ± 3.42% demyelinated axons in mutants vs. 22.68 ± 1.58%
in controls) (Figure 9b). Also at 21 dpl, only 8.24 ± 0.70% of axons remained demyelinated in control
mice, compared to 18.00 ± 1.91% in mutants. At this time point, focal lesions approach their full
remyelination potential (Crawford et al., 2016; Franklin and Ffrench-Constant, 2017). In agreement, further analysis of a later time point (56 dpl) revealed only a slight additional decrease in the
percentage of demyelinated fibers in control mice to 5.58 ± 1.02% (Figure 9b). Similarly, this value
decreased also in mutants to 12.04 ± 1.11% (Figure 9b). However, in direct comparison of controls
and mutants at 56 dpI, mutants still retained a larger percentage of demyelinated axons (12.04 ±
1.11% in mutants vs. 5.58 ± 1.02% in controls) (Figure 9b). Remyelinated profiles of both control
and mutant mice showed characteristically thin myelin (Figure 9a) (Franklin and Ffrench-Constant,
2017), with no significant difference detectable in the thickness of myelin by average g-ratio analysis
(Figure 9c) and by linear correlation of g-ratio versus axon diameter (Figure 9d) at the sampled time
points (14, 21 and 56 dpl). We conclude that FASN and consequently FA synthesis in OLs is essential
for efficient remyelination in adult mice.
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Figure 9. De novo fatty acid synthesis is essential to achieve efficient remyelination in the spinal cord. (a) Representative EM images of lesions in the
spinal cord of control (CT) and inducible conditional mutant (i-cMU) mice during remyelination at 14, 21 and 56 days post-lysolecithin injection (dpl).
i-cMUs show persistently increased numbers of demyelinated axons (examples false colored in orange) compared to CTs up to 56 dpl. Scale bars: 3
mm. (b) Corresponding graphs with quantification of percentage of demyelinated axons within the remyelinated lesion area at 14, 21 and 56 dpl. Data
points represent n = 3 mice for each, CT and i-cMU. The entire lesion area was quantified, at least 550 axons counted per animal (unpaired two-tailed
two sample Student’s t-test; 14 dpl: i-cMU vs. CT, p=0.0263, t = 3.439; 21 dpl: i-cMU vs. CT, p=0.0086, t = 4.803; 56 dpl: i-cMU vs. CT, p=0.0127,
t = 4.290), *p<0.05, **p<0.01. (c) g-ratio analysis of remyelinated fibers at 14, 21 and 56 dpl in i-cMU compared to CTs. Data points represent n = 3
mice for each, CT and i-cMU (unpaired two-tailed two sample Student’s t-test; 14 dpl: i-cMU vs. CT, p=0.1146, t = 2.011; 21 dpl: i-cMU vs. CT,
p=0.3146, t = 1.149; 56 dpl: i-cMU vs. CT, p=0.1481, t = 1.789). (d) Linear correlation of g-ratio versus axon diameter in remyelinating lesions of i-cMU
compared to CT mice, at 14, 21 and 56 dpl. At least 50 myelinated axons per mouse analyzed, n = 3 mice for each, CT and i-cMU. Bars represent
mean ± SEM. CT = control, i-cMU = inducible conditional mutant, dpl = days post-lysolecithin injection.
DOI: https://doi.org/10.7554/eLife.44702.024

Discussion
Oligodendrocytes require rapid access to large quantities of lipids over a short period of time to
achieve accurate production of the considerable membrane mass required to myelinate multiple
axons (Chrast et al., 2011; Nave and Werner, 2014; Schmitt et al., 2015). To which extent this
demand is supported by endogenous synthesis in OLs and/or lipid uptake is not fully understood
(Chrast et al., 2011; Schmitt et al., 2015). In support of a critical role for OL-endogenous lipid biosynthesis, the mTORC1/SREBP signaling axis was suggested to be critical for efficient CNS myelination (Camargo et al., 2017; Lebrun-Julien et al., 2014). Furthermore, OLs depend on cholesterol
synthesis for efficient radial growth of myelin (Saher et al., 2005). Postnatally, newly added cholesterol – the major sterol present in myelin – can only be synthesized within the CNS, while the other
main myelin lipids share FAs as building blocks that might be either locally synthesized or taken up
from the bloodstream (Currie et al., 2013; Harayama and Riezman, 2018). Here, we have
addressed the need for FA synthesis in OLs by depleting FASN in transgenic mice. This multifunctional enzyme is responsible for the synthesis of palmitate, the substrate for the production of more
complex FAs (Currie et al., 2013; Harayama and Riezman, 2018). We show that lack of FASN in
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OLs results in deficits in CNS myelination, including a decreased capacity for myelin to grow. Thus,
OLs strictly depend on de novo endogenous FA synthesis to achieve normal myelination.
Another source for non-essential FAs, and the only source available for essential ones, is the
uptake from the FA pool present in the circulation (Harayama and Riezman, 2018). We have previously demonstrated that increasing dietary lipids by administering a HFD cannot ameliorate the dysmyelination resulting from lack of FASN in myelinating Schwann cells of the PNS (Montani et al.,
2018). Thus, we were somewhat surprised to find that the same HFD experimental regimen was
able to achieve partial amelioration of the CNS hypomyelination caused by lack of FASN in OLs. Similarly, it has been shown that the HFD used in our study could partially substitute for the lack of
SCAP in another CNS cell population, the astrocytes (Camargo et al., 2012; Camargo et al., 2017).
The causative mechanisms for these differences between the PNS vs. CNS remain to be determined.
Future studies will need to take into account that the two tissues appear to have evolved distinct
compensatory mechanisms to deal with this situation. Specifically, adipocytes that are present in the
layers surrounding peripheral nerves (i.e. epineurial adipocytes) can carry out lipolysis, potentially to
provide supporting lipids when endogenous synthesis in Schwann cells fails (Montani et al., 2018)
or might become limiting. In contrast, the CNS contains astrocytes which can provide horizontal lipid
flux to OLs (Camargo et al., 2017). However, the specifics of qualitative (i.e. which lipid species are
involved) and quantitative contributions, both spatially and temporally, are challenging open
research questions. In addition, the relevance of such mechanisms to the maintenance of homeostatic physiology and in disease situations remain important topics to be investigated.
Given the relevance of efficient remyelination as a drug target in diseases such as multiple sclerosis (Cole et al., 2017; Franklin and Ffrench-Constant, 2017) and the currently clinically explored
potential of biotin – an important regulator of FA synthesis – in multiple sclerosis treatment
(Sedel et al., 2016), we were motivated to evaluate the significance of FA synthesis by OLs also in
remyelination. To realize this goal, we used the focal lysolecithin-induced demyelinating-remyelinating lesion model in the spinal cord of transgenic mice after depleting FASN specifically in aOPCs.
We show that de novo synthesis of FAs is crucial to sustain remyelinating aOPC-derived OLs and is
ultimately required for successful remyelination. Specifically, we found that after being able to differentiate correctly, the number of aOPCs-derived OLs was substantially reduced in mutants compared
to controls at onset of remyelination, persisting at later time points. Thus, endogenous FA synthesis
appears to be pivotal to maintain survival of newly differentiated and mature aOPCs-derived OLs
when myelination starts. At the myelin level, depletion of FASN in aOPCs and their progenies was
associated with reduced numbers of remyelinated axons in mutants compared to controls from 14
dpl (first time point analyzed) up to 56 dpl (latest time point analyzed). This rather strong phenotype
was not expected, since we anticipated that partial disruption of the blood-brain (-spinal cord) barrier in the lesioned CNS may lead to facilitated access of OLs to supplementary FA sources, that is
from the pool of FAs in the blood, either directly or from increased horizontal flux from astrocytes
(Camargo et al., 2017; Saher et al., 2012). Possibly, saturation of molecules mediating FA-uptake
and/or unknown regulatory mechanisms might restrict the FA uptake capacity of OLs not allowing
full compensation for the lack of endogenous synthesis. Such mechanisms may also be differentially
regulated in lesioned versus intact tissue. Future studies in this context should be aimed at achieving
a detailed understanding of the molecular mechanisms that regulate synthesis and trafficking of FAs
in the normal and diseased CNS, with a particular emphasis on OLs, astrocytes and blood vessels,
including endothelial cells and pericytes. Such knowledge is expected to broaden our understanding
of the fundamental mechanisms that regulate developmental myelination, pathological states in diseases, and remyelination after injury (Chrast et al., 2011; Schmitt et al., 2015).

Materials and methods
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Continued on next page
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Continued
Reagent type
(species) or resource

Additional
information

Designation

Source or reference

Identifiers

Genetic
reagent
(M. musculus)

Fasnlox/lox

PMID:16054078

MGI:3765070

Dr. Clay F.
Semenkovich,
Washington
University,
St. Louis USA

Genetic
reagent
(M. musculus)

PdgfraCreERT2

PMID:18849983

MGI:3832569

Dr. William D.
Richardson,
University College
London,
London UK

Genetic
reagent
(M. musculus)

Olig2Cre

Jackson
Laboratory

Stock#:011103;
MGI:3810299

PMID:18691547

Genetic
reagent
(M. musculus)

Rosa26-lox
PstoploxP-YFP

Jackson
Laboratory

Stock#:006148;
MGI:3621481

PMID:11299042

Sequencebased reagent

Genotyping
primer:
Fasn forward

PMID:29434029

5’-GGATAGCTGTGTAGTGTAACCAT-3’

Sequencebased reagent

Genotyping
primer:
Fasn reverse

PMID:29434029

5’-GGTCACCCAGCAGGAAAGGGC- 3’

Sequencebased reagent

Genotyping
primer:
Cre forward

PMID: 29434029

5’-TTCCCGCAGAACCTGAAGATGTTCG-3’

Sequencebased reagent

Genotyping
primer:
Cre reverse

PMID: 29434029

5’-GGGTGTTATAAGCAATCCCCAGAAATG-3’

Sequencebased reagent

Genotyping
primer:
Rosa26-lox
PstoploxP-YFP
forward

PMID: 28522536

5’-AAAGTCGCTCTGAGTTGTTAT-3’

Sequencebased reagent

Genotyping
primer:
Rosa26-loxPs
toploxP-YFP reverse
transgenic

PMID: 28522536

5’-GCGAAGAGTTTGTCCTCAACC-3’

Sequencebased reagent

PMID: 28522536
Genotyping
primer:
Rosa26-loxPstoploxP-YFP
reverse wildtype

Sequencebased reagent

qRT-PCR
primer:
SOX10 Forward

This paper

5’-CCGACCAGTACCCTCACCT-3’

Sequencebased reagent

qRT-PCR primer:
SOX10 Reverse

This paper

5’- TCAATGAAGGGGCGCTTGT-3’

Sequencebased reagent

qRT-PCR primer:
MYRF Forward

This paper

5’-ATGGAGGTGGTGGACGAGAC-3’

Sequencebased reagent

qRT-PCR primer:
MYRF Reverse

This paper

5’-GGCGTCCTCTTTGCCAATGT-3’

Sequencebased reagent

qRT-PCR primer:
MBP Forward

This paper

5’-ACACGAGAACTACCCATTATGGC-3’

Sequencebased reagent

qRT-PCR primer:
MBP Reverse

This paper

5’-CCAGCTAAATCTGCTGAGGGGA-3’

Sequencebased reagent

qRT-PCR primer:
Actin Forward

PMID: 28880149

5’-GTCCACACCCGCCACC-3’

5’-GGAGCGGGAGAAATGGATATG-3’

Continued on next page
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Continued
Reagent type
(species) or resource

Designation

Source or reference

Sequencebased reagent

qRT-PCR primer:
Actin Reverse

PMID: 28880149

Antibody

Rabbit polyclonal
anti-cleaved
Caspase 3

Cell signaling
Technology,
Danvers, MA, USA

Cat# 9661;
RRID:AB_2341188

1:500 dilution

Antibody

Mouse monoclonal
anti-CC1

Merck Millipore,
Billerica, MA, USA

Cat; # OP80;
RRID:AB_2057371

Development:
1:200 dilution;
Remyelination
1:300 dilution

Antibody

rabbit polyclonal
anti-FASN

Abcam, UK

Cat# Ab22759;
RRID:AB_732316

1:200 dilution

Antibody

Chicken
polyclonal anti-GFP

Abcam, UK

Cat# Ab13970;
RRID:AB_300798

1:1000 dilution

Antibody

mouse monoclonal
anti-ki67

Dako Agilent,
Santa Clara,
CA, USA

Cat# m7249;
clone MIB-5;
RRID:AB_2250503

1:200 dilution

Antibody

rat monoclonal
anti-MBP

Serotec/BioRad
Laboratories,
Hercules, CA, USA

Cat#
MCA409S;
RRID:AB_325004

Development:
1:200 dilution;
Remyelination
1:300 dilution

Antibody

Goat polyclonal
anti-Olig2

R and D Systems,
Minneapolis,
MN, USA

Cat# AF2418;
RRID:AB_2157554

1:25 dilution

Antibody

mouse monoclonal
anti-Olig2

Merck Millipore,
Billerica, MA, USA

Cat# MABN50;
1:1000 dilution
clone
211F1.1;
RRID:AB_10807410

Antibody

rabbit polyclonal
anti-Olig2

Merck Millipore,
Billerica, MA, USA

Cat# AB9610;
RRID:AB_570666

Development:
1:500 dilution;
Remyelination
1:400 dilution

Antibody

Rabbit monoclonal
anti-PDGFRa

Cell signaling
Technology,
Danvers, MA, USA

Cat# 3174;
RRID:AB_2162345

1:500 dilution

Commercial
assay or kit

Click-iT EdU
Assay

Thermo Fisher
Scientific, Waltham,
MA, USA

Cat# C10337

Commercial
assay or kit

Mouse blocking
reagent

Vector Laboratories,
Burlingame, CA, USA

Cat# MKB-2213

Commercial
assay or kit

Streptavidin/
Biotin blocking Kit

Vector Laboratories,
Burlingame, CA, USA

Cat# SP-2002

Commercial
assay or kit

Qiagen MiniKit
(RNeasy Mini Kit)

Qiagen, Hilden,
Germany

Cat# 74104

Commercial
assay or kit

TruSeq Stranded
mRNA Sample
Prep Kit

Illumina, San Diego,
CA, USA

Cat# 20020594

Commercial
assay or kit

Maxima RT-Kit

Thermo Fisher
Scientific, Waltham,
MA, USA

Cat# K1641

Chemical compound, drug Lysolecithin

Sigma-Aldrich,
Sant Louis, MO, USA

Cat# L4129

Chemical compound, drug Tamoxifen

Sigma-Aldrich,
Sant Louis, MO, USA

Cat# T5648

Chemical compound, drug Lipid standards

Avanti Polar Lipids,
Alabaster, AL, USA

Identifiers

Additional
information
5’-GGCCTCGTCACCCACATAG-3’

Continued on next page
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Continued
Reagent type
(species) or resource

Designation

Source or reference

Software,
algorithm

Lipid Data
Analyzer software

PMID: 29058722

Software,
algorithm

Photoshop CS5 or CS6

Adobe

Software,
algorithm

FIJI

ImageJ
(http://imagej.nih.gov/ij/)

Software,
algorithm

STAR Aligner(v2.5.1b)

PMID: 23104886

Software,
algorithm

RSEM (v1.2.22)

PMID: 21816040

Software,
algorithm

EdgeR

PMID: 19910308

Software,
algorithm

Metacore (vs6.33)

Thomson
Reuters

Other

Standard diet (STD)

KLIBA NAFAG,
Provimi KLIBA,
Switzerland

Cat# 3437

Other

High fat diet (HFD)

KLIBA NAFAG,
Provimi KLIBA,
Switzerland

Cat# 2127

Identifiers

Additional
information

Contacts for reagents and resource sharing
Requests for further information and reagents may be directed to the corresponding author Ueli
Suter (usuter@biol.ethz.ch). Fasnlox/lox mice are available from the Semenkovich laboratory after executing an MTA with Washington University. The PdgfraCreERT2 mice are available from the Richardson laboratory after executing an MTA with the University College London. From Jackson
Laboratory are available: Olig2Cre mice (JAX Stock #011103) and Rosa26-loxPstoploxP-YFP mice
(JAX Stock #006148).

FASN conditional knockout mice
For developmental studies, mice (Mus musculus) homozygous for the fatty acid synthase (Fasn)
floxed allele (Chakravarthy et al., 2005) (Strain of origin: 129X1/SvJ, subsequently crossed with
129X1/SvJ * C57BL/6 * DBA) were crossed with mice expressing Cre recombinase under the control
of the Olig2 promoter (Schüller et al., 2008) (Strain of origin: C57BL/6) to obtain Cre+:Fasnlox/lox
mutant mice, and Fasnlox/lox or Fasnlox/wt control mice. For experiments assessing recombination frequencies, a Rosa26-loxPstoploxP-YFP allele (Srinivas et al., 2001) (Strain of origin: C57BL/6) was
included.
For remyelination studies, mice homozygous for the Fasn floxed allele (Chakravarthy et al.,
2005) (Strain of origin: 129X1/SvJ, subsequently crossed with 129X1/SvJ * C57BL/6 * DBA) were
crossed with reporter mice homozygous for the Rosa26-loxPstoploxP-YFP allele and with mice
expressing CreERT2 recombinase, activatable upon tamoxifen injection, under the control of the
Pdgfra promoter (PdgfraCreERT2) (Rivers et al., 2008) (Strain of origin: C57BL/6). Control mice
were PdgfraCreERT2+:Rosa26-loxPstoploxP-YFP:FASNwt/wt for immunohistochemical analysis and
Rosa26-loxPstoploxP-YFP:FASNlox/lox for electron microscopy analysis. Mutant mice were
PdgfraCreERT2+:Rosa26-loxPstoploxP-YFP:FASNlox/lox for all analyses. All mice were injected with
tamoxifen. Fasn floxed mice were backcrossed for at least three generations to C57BL/6 background, and Olig2Cre, Rosa26-loxPstoploxP-YFP and PdgfraCreERT2 mice were kept on a C57BL/6
background.
Both male and female mice were used throughout all experiments. Mice were group-caged, kept
in a 12 hr light/dark cycle, with water and food provided ad libitum. Littermates and age-matched
mice were assigned to experimental groups according to age and genotype. No method of randomization was applied. Animals were fed a standard (STD) (Cat# 3437, KLIBA NAFAG, Provimi KLIBA,
Switzerland) or a high-fat diet (HFD) (Cat# 2127, KLIBA NAFAG, Provimi KLIBA, Switzerland), as
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previously described (Montani et al., 2018). Briefly, pregnant females were fed the high fat diet
from gestational day 14 until weaning of the pups 3 weeks after birth. Pups were subsequently separated from the mother and kept on a high fat diet until being sacrificed at 40 days of age. Diets content of fatty acids (in percentage) in HFD vs. STD was: C12 0.03 vs. 0.002, C14 0.440 vs. 0.008, C15
0.000 vs. 0.002, C16 8.220 vs. 0.719, C17 0.000 vs. 0.004, C18 4.500 vs. 0.157, C20 0.020 vs. 0.010,
C22 0.000 vs. 0.004, C24 0.000 vs. 0.012, C14:1 0.170 vs. 0.001, C16:1c7 1.000 vs. 0.052, C18:1c9
14.120 vs. 1.024, C20:1c9 0.000 vs. 0.013, C22:1c9 0.000 vs. 0.002, C18:2c9c12 4.810 vs. 2.107,
C18:3c9c12c15 0.590 vs. 0.212, C20:4(n-6) 0.560 vs. 0.009, C22:5(n-3) 0.000 vs. 0.001. Cholesterol
was present in the same percentage (0.030) in both HFD and STD.
Genotypes were determined by PCR on genomic DNA (Fasn primers: 5’-Forward GGATAGCTG
TGTAGTGTAACCAT-3’, Reverse 5’-GGTCACCCAGCAGGAAAGGGC-3’; Cre primers: Forward 5’TTCCCGCAGAACCTGAAGATGTTCG-3’, Reverse 5’-GGGTGTTATAAGCAATCCCCAGAAATG-3’,
Rosa26-loxPstoploxP-YFP primers: Forward 5’-AAAGTCGCTCTGAGTTGTTAT-3’, Reverse transgenic
5’-GCGAAGAGT TTGTCCTCAACC-3’, Reverse wild type 5’-GGAGCGGGAGAAATGGATATG-3’).
All animal experiments were performed with the approval and in strict accordance with the guidelines of the Zurich Cantonal Veterinary Office (ref ZH161/2014, ZH090/2017, ZH03/2012, ZH264/
2014, ZH207/2017).

Tamoxifen administration
CreERT2-mediated recombination in 8 to 10 week-old mice was induced by a single daily intraperitoneal injection of 2 mg tamoxifen (Cat# T5648, Sigma-Aldrich, Sant Louis, MO, USA; 20 mg/ml stock
solution in sunflower oil containing 10% ethanol) over 5 consecutive days.

Focal spinal cord demyelinating lesions
Four weeks after tamoxifen induction, demyelinated lesions were induced in the ventral funiculus of
the thoracic spinal cord at intervertebral level T12/T13 as previously described (Fancy et al., 2011).
Mice received a preoperative subcutaneous injection of 0.1 mg/kg (of body weight) of buprenorphine (Temgesic solution injectable 0.3 mg/ml, Indivior, Switzerland) in Ringer solution (Braun, Switzerland), and were anesthetized by isoflurane inhalation. A dorsal laminectomy was performed at the
T12/T13 level, and the dura pierced with an acupuncture needle. 1 ml of 1% lysolecithin (Cat# L4129,
Sigma-aldrich, Sant Louis, MO, USA) in 1x PBS, pH 7.4, was injected hemilaterally in the ventral
funiculus at a rate of 0.5 ml per minute, with a glass needle coupled to a Hamilton syringe, via a
three-way micromanipulator (Narishige, Japan). The overlaying musculature was sutured, and wound
clips were applied to close the skin above. Animals were allowed to recover on a heating pad at 37˚
C. Animals received twice daily a subcutaneous injection of 0.1 mg/kg (of body weight) of buprenorphine (Temgesic solution injectable 0.3 mg/ml, Indivior, Switzerland) for two days following the
injury. For additional analgesic treatment, animals were supplied with ad libitum 0.01 mg/ml buprenorphine (Temgesic solution injectable 0.3 mg/ml, Indivior, Switzerland) in drinking water for three
days following injury.

TEM and SEM microscopy
Mice were anaesthetized by terminal intraperitoneal injection of pentobarbital, 10% in saline solution
(0.9% NaCl) (Eskonarkon, Streuli Pharma, Switzerland). Mice were intracardially perfused with 0.1M
phosphate buffer (PB) pH 7.4, followed by a 2.5% glutaraldehyde/4% paraformaldehyde solution in
0.1M PB. After dehydration through an acetone series, tissues were post-fixed in 2% osmium tetroxide overnight, and embedded in Spurr’s resin (Electron Microscopy Sciences, Hatfield, PA, USA).
Ultrathin sections were cut on a Leica UC-7 (Leica microsystems, Germany) or a Reichert-Jung Ultra
cut E ultramicrotome (Leica microsystems, Germany, 65 nm-thick for transmission electron microscopy (TEM) or 99 nm-thick for scanning electron microscopy (TEM)). Sections transferred onto copper grids with a carbon film (Electron Microscopy Sciences, Hatfield, PA, USA) for TEM or ITO
coverslips (Optic Balzers, Germany) for SEM, were counterstained with 2% uranyl acetate and 1%
lead citrate. Images were acquired with a Morgagni 268 (FEI) for TEM, for analysis of developmental
myelination. For reconstruction of entire lesion areas for the remyelination analysis, SEM was used.
Images were acquired using the in-lens detector of a Merlin FEG SEM (Zeiss, Germany) operating at
2 KeV, attached to the ATLAS module (Zeiss, Germany). The entire lesion area was imaged as
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multiple individual images, with overlap between adjacent ones. Alignment and merging of these
images was performed using FIJI (ImageJ) and Photoshop CS5 or CS6 (Adobe). Brightness and contrast of EM images were adjusted for optimal detection of the structures.

Antibodies
The following antibodies were used: Rabbit anti-cleaved Caspase 3 (IHC 1:500, Cat# 9661, Cell signaling Technology, Danvers, MA, USA; RRID:AB_2341188), mouse anti-CC1 (IHC 1:200 in the analysis of development, 1:300 in the analysis of remyelination, Cat# OP80, Merck Millipore, Billerica,
MA, USA; RRID:AB_2057371), rabbit anti-FASN (IHC 1:200, Cat# Ab22759, Abcam, UK; RRID:AB_
732316), chicken anti-GFP (IHC 1:1000, Cat# Ab13970, Abcam, UK; RRID:AB_300798), mouse antiki67 (IHC 1:200, Cat# m7249, clone MIB-5, Dako Agilent, Santa Clara, CA, USA; RRID:AB_2250503),
rat anti-MBP (IHC 1:200 in the analysis of development, IHC 1:300 in the analysis of remyelination,
Cat# MCA409S, Serotec/BioRad Laboratories, Hercules, CA, USA; RRID:AB_325004), goat antiOlig2 (IHC 1:25, Cat# AF2418, R and D Systems, Minneapolis, MN, USA; RRID:AB_2157554; biotinylated), mouse anti-Olig2 (IHC 1:1000, clone 211F1.1, Cat# MABN50, Merck Millipore, Billerica, MA,
USA; RRID:AB_10807410), rabbit anti-Olig2 (IHC 1:500 in the analysis of development, IHC 1:400 in
the analysis of remyelination, Cat# AB9610, Merck Millipore, Billerica, MA, USA; RRID:AB_570666),
rabbit anti-PDGFRa (IHC 1:500, Cat# 3174, Cell signaling Technology, Danvers, MA, USA; RRID:AB_
2162345), donkey anti-chicken Alexa488 (IHC 1:1000, Cat# 703-545-155, Jackson ImmunoResearch,
West Grove, PA, USA; RRID:AB_2340375), goat anti-mouse Alexa488 (IHC 1:300, Cat# A11029,
Thermo Fisher Scientific, Waltham, MA, USA; RRID:AB_138404), donkey anti-mouse Alexa546 (IHC
1:1000, Cat# A10036, Thermo Fisher Scientific, Waltham, MA, USA; RRID:AB_2534012), goat antimouse Alexa546 (IHC 1:1000, Cat# A11030, Thermo Fisher Scientific, Waltham, MA, USA; RRID:AB_
144695), goat anti-mouse Alexa647 (IHC 1:1000, Cat# A21237, Thermo Fisher Scientific, Waltham,
MA, USA; RRID:AB_1500743), donkey anti-rabbit Alexa488 (IHC 1:1000, Cat# A21206, Thermo
Fisher Scientific, Waltham, MA, USA; RRID:AB_2535792), donkey anti-rabbit Alexa647 (IHC 1:1000,
Cat# A31573, Thermo Fisher Scientific, Waltham, MA, USA; RRID:AB_2536183), goat anti-rabbit
Alexa546 (IHC 1:1000, Cat# A11035, Thermo Fisher Scientific, Waltham, MA, USA; RRID:AB_
143051), goat anti-rabbit Alexa594 (IHC 1:300, Cat# A11012, Thermo Fisher Scientific, Waltham,
MA, USA; RRID:AB_141359), goat anti-rabbit Alexa647 (IHC 1:1000, Cat# A21244, Thermo Fisher
Scientific, Waltham, MA, USA; RRID:AB_141663), goat anti-rat Alexa647 (IHC 1:300, Cat# A21247,
Thermo Fisher Scientific, Waltham, MA, USA; RRID:AB_141778), Streptavidin-Alexa647 (IHC 1:1000,
Cat# S21374, Thermo Fisher Scientific, Waltham, MA, USA; RRID:AB_2336066).

Immunostaining
Cell proliferation was analyzed using the Click-iT EdU Assay (Invitrogen), according to manufacturer’s
protocol. Mice received a single intraperitoneal injection of EdU (50 mg/Kg of weight) and the tissue
of interest was harvested 2 hr after the injection.
Mice were anaesthetized by terminal intraperitoneal injection of pentobarbital, 10% in saline solution (0.9% NaCl) (Eskonarkon, Streuli Pharma, Switzerland). Mice were intracardially perfused with 1x
PBS pH 7.4, followed by 4% paraformaldehyde, 5% sucrose in 1x PBS. Dissected tissues were postfixed in 4% paraformaldehyde, 5% sucrose in 1x PBS overnight at 4˚C and cryoprotected in 30%
sucrose in PBS for 24 hr at 4˚C. Tissues embedded in O.C.T. Tissue Tek (Sakura, The Netherlands)
were cut on a cryostat in 10 mm sections with distance between serial sections of 100 mm, and transferred to SuperFrost Plus (Thermo Fisher Scientific, Waltham, MA, USA) coated slides. Slides were
stored at 80˚C until further use.
For immunostaining, slides were defrosted at room temperature (RT) for at least 30 min and
rinsed 3x with 1% Triton X-100 in 1x PBS. Blocking and permeabilization was done with 1% Triton
X-100, 10% goat or donkey serum, in 1x PBS for 30 min. Sections were incubated with primary antibodies, diluted in blocking solution, overnight at 4˚C. The following day, sections were washed 3 
10 min with 0.1% Triton X-100 in 1x PBS and incubated with secondary antibodies, diluted in blocking solution, for 2 hr at RT. Sections were washed twice with 0.1% Triton X-100 in 1x PBS, and incubated with 40 ,60 -diamidino-2-phenylindole (DAPI) for 10 min. After a last 10 min wash with 1x PBS,
sections were coverslipped with ImmuMount (Thermo Fisher Scientific, Waltham, MA, USA). For
CC1, cleaved caspase 3, and Ki67 stainings, an antigen retrieval step was added to the above
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protocol. Briefly, after thawing slides were incubated in a pre-heated antigen retrieval solution in a
water bath for 20 min (for analysis of development: Sodium citrate buffer (10 mM Tri-sodium citrate
dehydrate, 0.05% Tween-20, pH 6.0) incubated at 95˚C, for analysis of remyelination Tris-EDTA
buffer (10 mM Trizma Base (Sigma-aldrich, St Louis, MI, USA), 1 mM EDTA, 0.05% Tween-20, pH
9.0) incubated at 86˚C). For stainings with mouse anti-CC1 antibody performed for the analysis of
remyelination, sections were next incubated with mouse blocking reagent (Cat# MKB-2213, Vector
Laboratories, Burlingame, CA, USA) for 1 hr at RT followed by primary antibody incubation and further processed according to manufacturer’s recommendations in 1% Triton X-100 in 1x PBS to prevent cross-reaction of anti-mouse secondary antibodies with endogenous antibodies.
For stainings with biotinylated anti-Olig2 antibody, sections were treated with a Streptavidin/Biotin blocking Kit (Cat# SP-2002, Vector Laboratories, Burlingame, CA, USA) according to the manufacturer’s protocol.

Lipid analysis
For lipidomic analysis, myelin from spinal cords dissected from P60 control and mutant mice was isolated by sucrose density gradient centrifugation, as described previously (Larocca and Norton,
2007). Briefly, spinal cords were transferred in suspension buffer (0.3 M sucrose containing as adjuvants 20 mM Tris-HCl pH 7.4, 1 mM EDTA, 1 mM DTT, 100 mM phenylmethylsulfonyl fluoride
(PMSF), 10 mg/ml leupeptin, and 10 mg/ml antipain) and tissue disrupted in a glass and stainless steel
homogenizer. The homogenate was layered onto a 0.83 M sucrose solution with the same adjuvants,
and centrifuged at 75000 g for 30 min at RT. The obtained white band of crude myelin membranes
was collected and subjected to three cycles of osmotic shock in 20 mM Tris-HCl pH 7.4 with adjuvants, 1x at 75000 g and 2x at 12000 g at 4˚C. Myelin pellets were resuspended in suspension buffer
and subjected to a repetition of density centrifugation and osmotic shock. Finally, obtained myelin
pellets were resuspended in 0.83 M sucrose solution with adjuvants. This was overlaid with suspension buffer and centrifuged at 75000 g for 30 min at 4˚C. The myelin fraction was subjected to a last
repetition of osmotic shock and the pellet resuspended in Tris-HCl buffer and immediately frozen in
liquid nitrogen. Purified myelin was stored at 80˚C until further processing.
Lipid standards were obtained from Avanti Polar Lipids (Alabaster, AL, USA). Analysis of lipid species was performed according to published methods (Fauland et al., 2011; Triebl et al., 2017).
Samples were extracted with methyl tert-butyl ether (MTBE) (Matyash et al., 2008). Lipid extracts
were evaporated and resuspended in 1 ml chloroform/methanol (1/1; v/v). Each lipid extract was
then split for analysis of total fatty acids (350 ml), positive ESI LC-MS/MS (18 ml) and negative ESI LCMS/MS (18 ml). Lipid extracts for LC-MS/MS analysis were evaporated, spiked with a mix of quantitative LIPID MAPS internal standards and 2 ml of spiked samples were injected onto a Thermo 1.9 mm
Hypersil GOLD C8, 100  1 mm HPLC column mounted in an Dionex Ultimate 3000 UHPLC instrument (Thermo Fisher Scientific). Data acquisition was performed by Orbitrap Velos Pro (Thermo
Fisher Scientific) full scans at a resolution of 100 k and <5 ppm mass accuracy with external calibration. Nominal mass resolution product ion spectra were acquired in preview mode at the LTQ. A
chromatography with Electron Impact Mass Spectrometry (GC-EI/MS) of Total fatty acids
(free + esterified) were determined by gas chromatography - electron impact mass spectrometry
(GC-EI/MS). Lipid extracts were dried and suspended in 1 ml methanolic NaOH. After 10 min incubation at 80˚C, samples were cooled for 5 min on ice. Then, 1 ml BF3 was added and incubated for 10
min at 80˚C. Fatty acid methyl esters were extracted with 1 ml saturated NaCl and 2 ml hexane. The
hexane phase was dried and methyl esters dissolved in 1.5 ml hexane. A Trace-DSQ GC-MS (Thermo
Fisher Scientific) equipped with a 30 m column (model TR-FAME, Thermo Fisher Scientific) was used
for analysis. Helium was used as carrier gas at a flow of 1.3 ml/min, in split mode, at 250˚C injector
temperature. Initial oven temperature of 150˚C was held for 0.5 min and then temperature was
increased to 180˚C at a rate of 10 ˚C/min. This was followed by a further increase to 190˚C at a rate
of 0.5 ˚C/min and then increased to 250˚C at a rate of 40 ˚C/min and kept for 3 min. The mass spectrometer was run in EI mode and fatty acids were detected in full scan of m/z 80–400. Source temperature was set to 250˚C and the transfer line temperature to 200˚C. Internal standards used in LCMS were (product number, lipid shorthand nomenclature, amount/sample): LM-1100, PE 12:0/13:0,
160 pmol; LM-1102, PE 17:0/20:4, 160 pmol; LM-1103, PE 21:0/22:6, 160 pmol; LM-1104, PE 17:0/
14:1, 160 pmol; LM-1302, PS 17:0/20:4, 240 pmol; LM-1300, PS 12:0/13:0, 240 pmol; LM-1304, PS
17:0/14:1, 240 pmol; LM-1000, PC 12:0/13:0, 200 pmol; LM-1002, PC 17:0/20:4, 200 pmol; LM-
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1003, PC 21:0/22:6, 200 pmol; LM-1004, PC 17:0/14:1, 200 pmol; LM-1601, LPC 17:1, 80 pmol; LM6002, sphingolipid mix, 120 pmol; LM-1500, PI 12:0/13:0, 320 pmol; LM-1502, PI 17:0/20:4, 320
pmol; LM-1504, PI 17:0/14:1, 320 pmol.
LC = liquid chromatography, ESI = electrospray ionization, MS = mass spectrometry, FTICR = Fourier transform ion cyclotron resonance, GC = gas chromatography, EI = electron impact,
DSQ = dual stage quadrupole, m/z = mass/ charge number, LM-n = Lipid Maps-ID number,
PE = phosphatidylethanolamine, PS = phosphatidylserine, PC = phosphatidylcholine,
PI = phosphatidylinositol.
Data were processed by Lipid Data Analyzer software as previously described (Hartler et al.,
2017), relying on exact mass, retention time and MS/MS spectra. Annotation of lipid species followed the shorthand nomenclature of the International Lipid Classification and Nomenclature Committee (Liebisch et al., 2013). During lipid extraction procedure, the fraction containing proteins
was lyophilized. Proteins were dissolved in lysis buffer (1% Rapigest (Waters/Millipore, Billerica, MA,
USA), Tris pH 7.4, 0.1 mM EDTA) and quantified on a Nanodrop Lite (Nanodrop Technologies,
Thermo Fisher Scientific) spectrophotometer. Lipid amounts were normalized to the sample total
protein content.

Sequencing
Total RNA was isolated with a Qiagen MiniKit according to manufacturer’s protocols, quantity and
quality were determined with Nanodrop Lite (NanoDrop Technologies, Thermo Fisher Scientific),
Qubit 2.0 Fluorometer (Life Technologies, Carlsbad, CA, USA) and Bioanalyzer 2100 (Agilent, Santa
Clara, CA). The TruSeq Stranded mRNA Sample Prep Kit (Illumina, San Diego, CA, USA) was used in
the succeeding steps. Briefly, poly-A containing RNA molecules were purified from the total RNA
samples (100 ng) using oligo-dT attached magnetic beads. Isolated RNA was reverse-transcribed
into double-stranded cDNA, with actinomycin added during first-strand synthesis. The cDNA samples were fragmented, end repaired and polyadenylated before ligation of TruSeq adapters. Fragments containing TruSeq adapters on both ends were selectively enriched with PCR. The quality and
quantity of the enriched libraries were validated using Qubit 2.0 Fluorometer and Bioanalyzer 2100.
The product is a smear with an average fragment size of approximately 360 bp. The libraries were
normalized to 10 nM in Tris-Cl 10 mM, pH 8.5 with 0.1% Tween-20. Sequencing was performed on
an Illumina HiSeq 4000 in single end 125 bp mode. The raw reads were first cleaned by removing
adapter sequences, trimming low quality ends, and filtering reads with low quality (phred quality <20). Read-alignment was done with STAR (v2.5.1b). Ensembl genome build GRCm38 was used
as reference and gene annotations downloaded on 2015-06-25 from Ensembl. Applied STAR alignment options were: OutFilterType BySJout, outFilter MatchNmin30, outFilter Mismatch Nmax10,
outFilter MismatchNoverLmax0.05, alignSJDB overhangMin1, aligns overhangMin8, alignIntron
Max1000000, alignMatesGap Max1000000, outFilterMultimapN max50. Quantification of gene level
expression was carried out using RSEM (v1.2.22) (Li and Dewey, 2011). Differential expression was
computed using the generalized linear model implemented in the Bioconductor package EdgeR
(Robinson et al., 2010). To correct for multiple testing, the Benjamini-Hochberg algorithm was
applied and adjusted p-values computed. Only significantly differentially expressed transcripts
(FDR  0.05, no fold change threshold) were loaded onto Metacore (vs6.33) for enrichment analysis
of GeneOntology processes and Metacore pathways.

qRT-PCR
Total RNA was isolated with a Qiagen MiniKit according to the manufacturer’s protocols; quantity
and quality were determined with Nanodrop Lite (NanoDrop Technologies). RNA samples were
reverse-transcribed to cDNA with oligo(dT) random primers in the presence of RNaseOUT (Thermo
Fisher Scientific, Waltham, MA, USA) with the Maxima RT kit (Thermo Fisher Scientific, Waltham,
MA, USA). Targeted sequences were amplified with exon/exon boundary-spanning probes and
detected by measurement of SYBRgreen on a LightCycler 480 (Roche, Switzerland). Cp values were
determined with the LightCycler 480 software (Roche, Switzerland). Primers used were: SOX10 Forward 5’-CCGACCAGTACCCTCACCT-3’, Reverse 5’-TCAATGAAGGGGCGCTTGT-3’, MYRF Forward
5’-ATGGAGGTGGTGGACGAGAC-3’, Reverse 5’-GGCGTCCTCTTTGCCAATGT-3’, MBP Forward 5’-
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ACACGAGAACTACCCATTATGGC-3’, Reverse 5’-CCAGCTAAATCTGCTGAGGGGA-3’, Actin Forward 5’-GTCCACACCCGCCACC-3’, Reverse 5’-GGCCTCGTCACCCACATAG-3’.

Statistical analysis
All experiments were quantified blindly to the genotype and treatment group. Statistics were analyzed using GraphPad Prism vs6.01. Data were assumed to be normally distributed, but not formally
tested. Variance was assumed to be equal between groups of data. No statistical methods were
used to predetermine sample size, but our sample sizes are similar than those generally employed in
the field. Statistical significance was determined using an unpaired two-tailed two sample Student’s
t-test for two group comparisons. Multiple groups analysis was performed with analysis of variance
(ANOVA) and post-hoc test as detailed in text and figures. Data show mean ±SEM. Significance was
set at p<0.05 *, p<0.01 **, p<0.001 ***.

Data availability
RNA-sequencing data are available on NCBI’s GEO database, accession number GSE112725.
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